Bielsko-Biala, Poland Clinical Trials

A listing of Bielsko-Biala, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Featured trial
Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and/or Cancer

The University of Tennessee Health Science Center in Memphis, TN has a research opportunity for people to participate in the study: Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and Cancer. Specifically, they are looking for individuals over the age of 60 for 1 of 3 groups: (1) those …

AIDS
primary cancer
cancer
Online studies
University of Tennessee Health Science Center
(online study) Contact site
  • 41 views
  • 28 Sep, 2022
  • 1 location
  • Online study
Featured trial
ARE YOU CARING FOR A LOVED ONE WITH DEMENTIA OR MCI?

You may be eligible to participate in a research study evaluating the effects of a new in-hometechnology system for caregivers of people with dementia or mild cognitive impairment. Thestudy is being conducted by Dr. Robert Levenson (University of California, Berkeley,Department of Psychology) and Gene Wang (People Power Company of Care …

Accepts healthy volunteers
mild cognitive impairment
dementia
alzheimer's disease
cognitive impairment
University of California, Berkeley
(online study) Contact site
  • 48 views
  • 05 Dec, 2022
  • 1 location
  • Online study
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

COAST Investigational Site
 (2.9 away) Contact site
  • 35 views
  • 07 Oct, 2022
  • +157 other locations
A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD Evaluate the distribution of Lp(a) …

American Heart of Poland Spolka Akcyjna Polsko-Amerykanskie Kliniki Serca
 (2.5 away) Contact site
  • 0 views
  • 13 Oct, 2022
  • +482 other locations
A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer

The primary hypotheses are that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and with respect to overall survival (OS) in …

Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1907)
 (5.0 away) Contact site
  • 1 views
  • 25 Oct, 2022
  • +97 other locations
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall …

cancer chemotherapy
atezolizumab
etoposide
pembrolizumab
carboplatin
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1707)
 (5.0 away) Contact site
  • 1 views
  • 24 Oct, 2022
  • +87 other locations
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying …

diabetes
cardiovascular disease
infarct
atherosclerosis
st elevation myocardial infarction
American Heart of Poland Sp. z o.o.
 (1.9 away) Contact site
  • 204 views
  • 24 Oct, 2022
  • +436 other locations
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is …

mk-3475
paclitaxel
epidermal growth factor
carboplatin
epidermal growth factor receptor
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205)
 (4.5 away) Contact site
  • 1 views
  • 27 Oct, 2022
  • +106 other locations
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

diabetes
infarct
arterial disease
stroke
acute coronary syndrome
6160082 - II Oddział Kardiologiczny PAKS
 (2.5 away) Contact site
  • 1233 views
  • 27 Oct, 2022
  • +1646 other locations